Sign Out
Special precautions for disposal and other handling: Recommendations for safe handling: Skin contact with the solution should be avoided and protective gloves must be worn. Standard procedures for dealing with anticancer agents should be adopted.
Reconstitution procedure: The powder should be aseptically reconstituted with 10 ml of water for injections. Upon reconstitution, each ml contains approximately 5 mg of decitabine at pH 6.7 to 7.3. Within 15 minutes of reconstitution, the solution must be further diluted with cold infusion fluids [sodium chloride 9 mg/ml (0.9%) solution for injection or 5% w/v Dextrose Injection and Lactated Ringer Injection] to a final concentration of 0.1 to 1.0 mg/ml.
Decitabine should not be infused through the same intravenous access/line with other medicinal products.
Disposal: This medicinal product is for single use only. Any unused product or waste material should be disposed of in accordance with local requirements.
Incompatibilities: This medicinal product must not be mixed with other medicinal products except those previously mentioned in Special precautions for disposal and other handling: Reconstitution procedure.
